Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)GlobeNewsWire • 07/17/24
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceGlobeNewsWire • 07/11/24
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)GlobeNewsWire • 07/10/24
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical TrialGlobeNewsWire • 06/25/24
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association CongressGlobeNewsWire • 05/28/24
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor ConferenceGlobeNewsWire • 05/23/24
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical MeetingGlobeNewsWire • 05/15/24
Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/24
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceGlobeNewsWire • 04/10/24
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/28/24
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressGlobeNewsWire • 03/25/24
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceGlobeNewsWire • 03/13/24
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)GlobeNewsWire • 03/07/24
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsGlobeNewsWire • 03/04/24
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingGlobeNewsWire • 02/14/24
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT ConferenceGlobeNewsWire • 01/29/24
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming MilestonesGlobeNewsWire • 01/23/24
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on DialysisGlobeNewsWire • 12/18/23
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023GlobeNewsWire • 11/29/23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/23
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)GlobeNewsWire • 10/23/23